These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 8838639

  • 21. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
    Fauler G, Abletshauser C, Erwa W, Löser R, Witschital K, März W.
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
    [Abstract] [Full Text] [Related]

  • 22. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits.
    Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S.
    Br J Pharmacol; 1996 Nov; 119(6):1269-75. PubMed ID: 8937733
    [Abstract] [Full Text] [Related]

  • 23. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
    Dujovne CA, Davidson MH.
    Am J Med; 1994 Jun 06; 96(6A):37S-40S. PubMed ID: 8017465
    [Abstract] [Full Text] [Related]

  • 24. Fluvastatin: a review of its use in lipid disorders.
    Langtry HD, Markham A.
    Drugs; 1999 Apr 06; 57(4):583-606. PubMed ID: 10235694
    [Abstract] [Full Text] [Related]

  • 25. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
    Gerson RJ, MacDonald JS, Alberts AW, Chen J, Yudkovitz JB, Greenspan MD, Rubin LF, Bokelman DL.
    Exp Eye Res; 1990 Jan 06; 50(1):65-78. PubMed ID: 2307197
    [Abstract] [Full Text] [Related]

  • 26. Post-mortem biochemistry of beagle dog lenses after treatment with Fluvastatin (Sandoz) for 2 years at different dose levels.
    Hockwin O, Evans M, Roberts SA, Stoll RE.
    Lens Eye Toxic Res; 1990 Jan 06; 7(3-4):563-75. PubMed ID: 2151608
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S, Gamez R, Mas R, Goicochea E.
    Int J Tissue React; 2003 Jan 06; 25(3):81-9. PubMed ID: 14756189
    [Abstract] [Full Text] [Related]

  • 31. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis A.
    Am J Cardiol; 1995 Jul 13; 76(2):62A-64A. PubMed ID: 7604801
    [Abstract] [Full Text] [Related]

  • 32. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs.
    Walsh KM, Albassam MA, Clarke DE.
    Toxicol Pathol; 1996 Jul 13; 24(4):468-76. PubMed ID: 8864188
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E, Muratti EN, Eliav O, Peters TK.
    Am J Cardiol; 1995 Jul 13; 76(2):84A-88A. PubMed ID: 7604807
    [Abstract] [Full Text] [Related]

  • 34. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
    Muratti EN, Peters TK, Leitersdorf E.
    Am J Cardiol; 1994 May 26; 73(14):30D-38D. PubMed ID: 8198022
    [Abstract] [Full Text] [Related]

  • 35. Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet.
    Díaz-Zagoya JC, Asenjo-Barrón JC, Cárdenas-Vázquez R, Martínez F, Juárez-Oropeza MA.
    Life Sci; 1999 May 26; 65(9):947-56. PubMed ID: 10465354
    [Abstract] [Full Text] [Related]

  • 36. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, Dallongeville J.
    Am J Cardiol; 1995 Jul 13; 76(2):65A-70A. PubMed ID: 7604802
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
    Yamamoto A, Hoshi K, Ichihara K.
    Eur J Pharmacol; 1998 Nov 13; 361(1):143-9. PubMed ID: 9851551
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.
    Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P.
    J Cardiovasc Pharmacol; 2001 May 13; 37(5):502-11. PubMed ID: 11336101
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.